Latest news

• Eylea growth closes the gap with Lucentis

  Combined sales of Bayer's five growth products - Eylea, pulmonary hypertension drug Adempas (riociguat), anticoagulant Xarelto (rivaroxaban) and cancer therapies Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride) - came in at

• Bayer's Eylea cleared for wider use in Europe

  For the full year, revenues were up 5% to 42.2bn. The company's five most recently launched drugs - Eylea; anticoagulant Xarelto (rivaroxaban); cancer drugs Stivarga (regorafenib) and Xofigo (radium Ra ... 223 dichloride); and pulmonary hypertension

• Personalised cancer medicines showcased in BBC investigation

  Astellas and Medivation's advanced prostate cancer drug Xtandi (enzalutamide) was highlighted being used with Bayer's Xofigo (Radium Ra 223 Dichloride) for an elderly patient with late-stage prostate cancer

• Exelixis axes staff as lead cancer programme fails

  already revitalised by the recent introductions of Zytiga, Xtandi and Bayer's radiopharmaceutical Xofigo (radium Ra 223 dichloride).

• Bayer raises sales predictions for new pharma products

  The new products - anticoagulant Xarelto (rivaroxaban), eye medicine Eylea (aflibercept), cancer drugs Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride) and pulmonary hypertension therapy Adempas (riociguat) - are now expected to add